WeGovy, also known as semaglutide, is a prescription medication used for weight management. According to Drug Patent Watch [1], WeGovy was approved by the FDA in June 2021, and it is a relatively new drug on the market.

The Journal of Managed Care & Specialty Pharmacy [2] published a study in 2022 that analyzed the cost-effectiveness of WeGovy compared to other weight management medications. The study found that WeGovy was cost-effective when compared to other weight management medications, including liraglutide, phentermine/topiramate, and bupropion/naltrexone. The study also found that WeGovy had a higher probability of being cost-effective compared to other medications when the willingness-to-pay threshold was higher.

In addition, the Institute for Clinical and Economic Review (ICER) [3] published a report in 2021 that evaluated the clinical effectiveness and value of several treatments for obesity management, including WeGovy. The report found that WeGovy was more effective than other weight management medications and was associated with greater weight loss. However, the report also noted that WeGovy was more expensive than other medications, and its cost-effectiveness was uncertain.

In conclusion, the available studies suggest that WeGovy is a cost-effective weight management medication compared to other treatments, but its cost-effectiveness may be uncertain when compared to some other medications. It is important to consult with a healthcare provider to determine if WeGovy is the right treatment option for an individual's weight management needs.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/WEGOVY
[2] https://www.jmcp.org/doi/full/10.18553/jmcp.2022.28.7.740
[3] https://icer.org/news-insights/press-releases/strongicer-publishes-final-evidence-report-and-policy-recommendations-on-treatments-forbrobesity-managementstrong/.